Skip to main content
Amit Patel, MD, Oncology, Jersey City, NJ

AmitAPatelMD

Oncology Jersey City, NJ

Hematologic Oncology

President, Medical/Dental Staff at RWJ Barnabas Health - Jersey City Medical Center Attending Physician, Hudson Hematology Oncology, LLC

Dr. Patel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Patel's full profile

Already have an account?

  • Office

    1 Exchange Place
    Jersey City, NJ 07302
    Phone+1 732-390-7750
    Fax+1 201-201-7234

Summary

  • Dr. Amit Patel is an oncologist in Jersey City, NJ and is affiliated with multiple hospitals in the area, including Jersey City Medical Center, CarePoint Health Bayonne Medical Center, and CarePoint Health Christ Hospital. He received his medical degree from St. George's University School of Medicine and has been in practice 12 years. He specializes in hematologic oncology and is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and multiple myeloma.

Education & Training

  • Icahn School of Medicine at Mount Sinai/St Luke’s-Roosevelt Hospital Center
    Icahn School of Medicine at Mount Sinai/St Luke’s-Roosevelt Hospital CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
  • Rutgers Health/New Jersey Medical School
    Rutgers Health/New Jersey Medical SchoolResidency, Internal Medicine, 2005 - 2008
  • St. George's University School of Medicine
    St. George's University School of MedicineClass of 2005

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 2012 - 2025

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2013-2014

Publications & Presentations

PubMed

Press Mentions

  • Batu Biologics Receives FDA Clearance for First Multi-Pronged Immunotherapy Targeting the Blood Vessels That Feed Cancer
    Batu Biologics Receives FDA Clearance for First Multi-Pronged Immunotherapy Targeting the Blood Vessels That Feed CancerNovember 7th, 2017